A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Bepirovirsen (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms B-Focus
- Sponsors GSK
Most Recent Events
- 25 Apr 2025 Planned End Date changed from 3 May 2027 to 27 Apr 2027.
- 25 Apr 2025 Planned primary completion date changed from 27 Jan 2027 to 20 Jan 2027.
- 09 Oct 2024 Status changed from not yet recruiting to recruiting.